Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) announced it has entered into an exclusive global license ...

For the first time, a drug to treat adult patients with familial chylomicronemia syndrome (FCS), a severe and rare condition that leads to extremely high levels of blood fats called triglycerides, has ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

－ストレスを受けた親が生存能力の高い子を生む仕組み－ 理化学研究所（理研）生命機能科学研究センター老化分子生物学研究チームの岡部恵美子リサーチアソシエイト、宇野雅晴研究員、西田栄介チームリーダーらの研究チームは、マイルドな環境 ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

Madrigal Pharmaceuticals MDGL announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) ...

For the first time, a drug to treat adult patients with familial chylomicronemia syndrome (FCS), a severe and rare condition that leads to extremely high levels of blood fats called triglycerides, has ...

Ohio State University researchers develop RNA micelles, offering targeted chemotherapy for metastatic colorectal cancer.